|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
Valuation Estimation |
EPS (Current/Estimated)
-0.44/--
|
Enterprise Value
--
|
Balance Sheet |
Book Value Per Share
N/A
|
Cash Flow |
Cash Flow Yield
--
|
Income Statement |
Total Revenue
20.00K
|
Operating Revenue Per Share
--
|
Industry Comparison
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
Quotes are at least 15-min delayed:2024/05/16 19:25 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
|
|||
NeOnc Technologies Holdings Inc. is the developer of a novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. The company product includes NEO100, which commenced Phase 2a clinical trials, which is used for treating glioblastoma, and has Orphan Drug and Fast Track designation from the United States Food and Drug Administration ("FDA"). |